+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Gene Therapy Market - Forecasts from 2022 to 2027

  • PDF Icon


  • 152 Pages
  • December 2022
  • Region: Global
  • Knowledge Sourcing Intelligence LLP
  • ID: 5716732

The global gene therapy market is expected to grow at a CAGR of 18.39% over the forecast period to reach US$11.769 billion by 2027 from US$3.611 billion in 2020.

Gene therapy refers to a medical process that modifies or teat an individual’s underlying genetic problem thereby preventing disease. Such therapy has high applicability in the treatment of major diseases such as cancer, diabetes, heart disease, and HIV among others as its ability to replace unhealthy genes with new ones provides the body with the ability to fight such diseases. Unhealthy food consumption, lifestyle factors, and the rising prevalence of obesity, coupled with the rapid increase in the population and economic downturn have increased the prevalence of chronic and infectious diseases such as cancer, diabetes, HIV, and heart disease. For instance, according to the World Health Organization, in 2020, the number of deaths that occurred due to cancer globally stood at 10 million with which death count by breast cancer stood at 2.26 million followed by lung cancer at 2.21 million. Furthermore, according to US Government’s HIV.gov data, in 2021, 1.2 million people in the United States were diagnosed with HIV. Moreover, according to the 2020 Health and Glance report by European Commission, in 2019, the total number of people diagnosed with diabetes stood at 32.3 million which showed significant growth of 92.2% from the cases reported in 2000. Owing to the rapidly growing prevalence of such major diseases, the demand for gene therapy products is also projected to increase, thereby boosting the global gene therapy market growth during the forecast period.

Based on vector type, the global gene therapy market is segmented into viral and non-viral vectors. The non-viral vector is expected to grow at a relatively higher rate during the forecast period of the global gene therapy market. Non-viral vector has low cost, is easy to produce, has better cell or tissue targeting, and provides biosafety advantages over viral vector which makes the non-viral vector much safer to be used in gene delivery. Owing to its rich performance benefits, the non-viral vector has a higher preference over the viral vector, and with the increase in the number of major communicable and non-communicable diseases such as cancer, diabetes, and AIDS, the demand for non-viral vectors for gene therapy is also expected to increase, thereby improving its segment as well as the overall market growth during the forecast period.

The growing establishment of gene therapy manufacturing plants by major companies is boosting the global gene therapy market growth. Various companies realizing the importance of gene therapy and its effectiveness against a wide range of deadly diseases are actively investing in innovations and plant establishments to increase their production of gene therapy products. For instance, in June 2022, REGEXBIO announced the establishment of its new gene therapy manufacturing center in Rockville, Md where the company will boost the manufacturing of its adeno-associated virus vectors using the company’s NAV technology. Furthermore, in December 2021, Pfizer opened its new state-of-the-art gene manufacturing facility in Durham, NC, where the company will boost the production of its multiple gene therapy medicine. Such manufacturing plant establishments will increase the demand and scope of usage of gene therapy in the future, thereby boosting the market growth of the global gene therapy market during the forecast period.

Recent developments:

  • In October 2022, Elli Lily and Company signed an agreement for the acquisition of Akouos for a sum of US$610 million. The acquisition will enable Elli Lily to add major gene therapy products of Akouos such as AK-OTOF which is used for treating hearing loss caused due to otoferlin gene mutations.
  • In August 2022, Cytiva collaborated with Forecyte Bio to accelerate the manufacturing and development of the gene therapy industry in the United State and China markets. The company’s collaboration will increase the patient’s access to gene therapy.
  • Thermo Fisher Scientific, in January 2022, acquired PeproTech for uS$1.85 billion which is one of the leading providers of recombinant proteins used in the development of gene therapies. The acquisition came as strategic by Thermo Fisher to combine its cell culture technologies with PeproTech’s recombinant proteins that will revolutionize the gene therapy products of the company.
  • In December 2021, Novartis entered into a strategic agreement to acquire UK-based gene therapy Gyroscope Therapeutics. The acquisition will enable Novartis to add the GT005 gene therapy product of Gyroscope to its portfolio, which is used for geographic atrophy.

Covid-19 Impact on the Gene Therapy Market

The COVID-19 pandemic led to a global lockdown and restrictions implemented by the governing authorities led to a decrease in diagnostic and medical treatment of major diseases such as cancer, diabetes, and HIV all of which, gene therapy has high applicability. For instance, according to the data provided by HIV.gov which is US Federal government’s official site for HIV, in 2020, the number of people who received HIV diagnosis in the US stood at 30,635 which showed a decrease of 17% in comparison to the 2019’s diagnosis. Such a decrease in diagnostic treatment reduced the demand for gene therapy in major countries like the US, thereby negatively impacting the growth of the global gene therapy market. However, with the restriction being lifted, the market is expected to show steady growth during the forecast period.

Market Segmentation:

By Therapy Type

  • Ex Vivo
  • In Vivo
  • In Situ

By Vector Type

  • Viral
  • Non-Viral

By Technique Type

  • Gene Augmentation
  • Gene Inhibition
  • Specific Cell Kill

By Disease Type

  • Cancer
  • Heart Disease
  • Diabetes
  • HIV
  • Others

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • Israel
  • United Arab Emirates
  • Others
  • Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • Australia
  • Indonesia
  • Thailand
  • Taiwan
  • Others
Frequently Asked Questions about the Global Gene Therapy Market

What is the estimated value of the Global Gene Therapy Market?

The Global Gene Therapy Market was estimated to be valued at $3.61 billion in 2020.

What is the growth rate of the Global Gene Therapy Market?

The growth rate of the Global Gene Therapy Market is 18.3%, with an estimated value of $11.77 billion by 2027.

What is the forecasted size of the Global Gene Therapy Market?

The Global Gene Therapy Market is estimated to be worth $11.77 billion by 2027.

Who are the key companies in the Global Gene Therapy Market?

Key companies in the Global Gene Therapy Market include Novartis, Pfizer Inc, MeiraGTx Limited, San Rocco Therapeutics, American Gene Technologies, IVERIC bio, Inc, Lysogene, AVROBIO Inc and Spark Therapeutics, Inc..

Table of Contents

1.1. Market Overview
1.2. Covid-19 Scenario
1.3. Market Definition
1.4. Market Segmentation

2.1. Research Data
2.2. Assumptions

3.1. Research Highlights

4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Forces Analysis
4.3.1. Bargaining Power of End-Users
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5.1. Introduction
5.2. Ex Vivo
5.3. In Vivo
5.4. In Situ

6.1. Introduction
6.2. Viral
6.3. Non-Viral

7.1. Introduction
7.2. Gene Augmentation
7.3. Gene Inhibition
7.4. Specific Cell Kill

8.1. Introduction
8.2. Cancer
8.3. Heart Disease
8.4. Diabetes
8.5. HIV
8.6. Others

9.1. Introduction
9.2. North America
9.2.1. USA
9.2.2. Canada
9.2.3. Mexico
9.3. South America
9.3.1. Brazil
9.3.2. Argentina
9.3.3. Others
9.4. Europe
9.4.1. Germany
9.4.2. France
9.4.3. United Kingdom
9.4.4. Italy
9.4.5. Spain
9.4.6. Others
9.5. Middle East and Africa
9.5.1. Saudi Arabia
9.5.2. Israel
9.5.3. United Arab Emirates
9.5.4. Others
9.6. Asia Pacific
9.6.1. China
9.6.2. Japan
9.6.3. South Korea
9.6.4. India
9.6.5. Australia
9.6.6. Indonesia
9.6.7. Thailand
9.6.8. Taiwan
9.6.9. Others

10.1. Major Players and Strategy Analysis
10.2. Emerging Players and Market Lucrativeness
10.3. Mergers, Acquisitions, Agreements, and Collaborations
10.4. Vendor Competitiveness Matrix

11.1. Novartis
11.2. Pfizer Inc.
11.3. MeiraGTx Limited
11.4. San Rocco Therapeutics
11.5. American Gene Technologies
11.6. IVERIC bio, Inc
11.7. Lysogene
11.8. AVROBIO Inc
11.9. Adverum Biotechnologies Inc
11.10. Sprak Therapeutics, Inc.

Companies Mentioned

  • Novartis
  • Pfizer Inc
  • MeiraGTx Limited
  • San Rocco Therapeutics
  • American Gene Technologies
  • IVERIC bio, Inc
  • Lysogene
  • Adverum Biotechnologies Inc
  • Spark Therapeutics, Inc.